| Press Releases

Worldwide Clinical Trials Ranked as Top CRO for Overall Performance In 2024 Industry Standard Research Phase II/III Benchmarking Report

Global contract research organization recognized as highest-performing Phase II/III CRO in multiple categories by key clinical development outsourcing decision makers

RESEARCH TRIANGLE PARK, N.C. – 12 June 2024Worldwide Clinical Trials (Worldwide), a global, full-service contract research organization (CRO), has been recognized in a variety of areas for its Phase II/III clinical research services in the 2024 Industry Standard Research (ISR) Benchmarking Report. ISR’s web-based, quantitative survey was conducted in Q4 2023 and included responses from 232 key decision-makers for Phase II/III CRO services from small, midsize, and large biopharma companies. View the full report here.

Based on ISR’s primary market research with key Phase II/III clinical development outsourcing decision-makers, Worldwide’s rankings include (but are not limited to):

  • No. 1 rated Phase II/III CRO for Overall Performance
  • No. 1 rated Phase II/III service provider for Project Manager Quality
  • No. 1 rated Phase II/III CRO for Project Delivery in Europe
  • No. 1 rated Phase II/III CRO for Biostatistics
  • Joint 1st position for Operational Excellence (with one other Phase II/III service provider)
  • Second highest performing Phase II/III CRO for Staff Characteristics
  • Second highest rated Phase II/III CRO for “Easy to Work With” (with three other companies)
  • Top 3 performer for Phase II/III CRO Services

“The ISR report comes at a time when clinical development is becoming increasingly complex, making it even more important for CROs to understand what sponsors need to run their clinical trials – this is what makes a truly successful sponsor/CRO partnership,” said Peter Benton, president and CEO of Worldwide. “At Worldwide, we’re committed to understanding these dynamics as industry trends shift, and we’re aware that our set-up can make or break a customer’s experience. For example, sponsors have told us they appreciate our personalized partnership model – the customer service we offer, our proactive communication and collaboration, the access they have to our technical experts and leaders, and our flexibility to adapt in an everchanging clinical landscape. These high marks in the ISR report are a testament to what we’re doing and that it’s working.”

“After working with Worldwide Clinical Trials for many years, it’s easy to see why they consistently perform so well in the ISR Phase II/III benchmarking report, especially in the areas of Overall Performance and Project Manager Quality. The Worldwide team has always been passionate about their work and the studies they conduct for their customers,” said Domingo Rodriguez, M.D., Executive Vice President of Global Clinical Operations, Veru Inc., a Worldwide sponsor. “If I was asked to describe the perfect CRO, it’d be a partnership in which trust, and flexibility go both ways; a CRO that is an extension of our team – and that’s exactly what we have with Worldwide.”

Worldwide’s partnership approach with its customers is anchored in transparent communication, responsiveness, and personalized attention. Earlier this year, and separate from the ISR data, Worldwide released the results of its 2024 industry survey, a report that examines the changing perceptions about large and midsize CROs within the pharmaceutical and biotech sectors. The survey data revealed current challenges sponsors are facing with large CROs while highlighting the importance of CRO partnerships and flexibility – underscoring the benefits of Worldwide’s business model.

For its ISR rankings, Worldwide was recently recognized for excellence in nine categories in the 2024 CRO Leadership Awards, presented by Clinical Leader, marking the 11th consecutive year the CRO has been rated as a top-performer. For details on Worldwide’s awards, click here.

About Worldwide Clinical Trials:
Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans nearly 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.

Media Contact:
Jill Mastrangelo

Recent Press Releases


Our extensive collection of scientific articles and papers